Fund Solutions

Spex Capital Unveils Global €100m Healthtech Fund 

Spex Capital, an early-stage investor in healthtech solutions, has launched the Spex Venture HealthTech Fund. Spex Capital is looking to raise €100 million (US$106.3 million) for the fund which will invest globally in early-stage healthtech ventures, for seed to series A, up to €5 million. The fund is a designated Article 9 impact fund under the EU’s Sustainable Finance Disclosure Regulation.  Claudio D’Angelo, Founder and CEO of Spex Capital, said: “Even before Covid-19, the drive for countries to make better use of digital technology in healthcare had already begun. With this fund, our partnership with MedCity, and a broad network of high calibre senior advisors, we will have unparalleled access to invest in the best startups within this space.” Through a two-year partnership with MedCity, the life sciences cluster organisation for London, Spex Capital benefits from connections to the NHS in England and extensive reach across the wider ecosystem. Joint activities include an international investment programme that contributes to the flow of around 1,000 healthcare companies developing breakthrough technologies every year. 

The practical information hub for asset owners looking to invest successfully and sustainably for the long term. As best practice evolves, we will share the news, insights and data to guide asset owners on their individual journey to ESG integration.

Copyright © 2024 ESG Investor Ltd. Company No. 12893343. ESG Investor Ltd, Fox Court, 14 Grays Inn Road, London, WC1X 8HN

To Top